Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients

International Immunopharmacology

Volumn 1, Issue 7, 2001, Pages 1235-1247

  Pittet, Mikaël J ^a   Speiser, Daniel E ^a   Valmori, Danila ^a   Rimoldi, Donata ^a   Liénard, Danielle ^a   Lejeune, Ferdy ^a   Cerottini, Jean Charles ^a   Romero, Pedro ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

Cytolytic T lymphocyte; Human; Immunotherapy; Peptide antigen; Tetramer; Tumor immunity

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; PEPTIDE; TETRAMER; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; BLOOD; CANCER; CANCER INHIBITION; CELL ACTIVATION; CELL FUNCTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR LOCALIZATION; VACCINATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY; MYOSIN HEAVY CHAINS; NEOPLASMS; PEPTIDES;

EID: 0035021010     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00048-0     Document Type: Review

References (96)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. A new look at T cells
3. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
4. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen
5. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro
6. A kinetic basis for T cell receptor repertoire selection during an immune response
7. Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer
8. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers
9. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis
10. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen
11. HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: Direct detection of immunodominant antigen-responsive cells
12. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers
13. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
14. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors
15. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
16. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
17. Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding
18. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs
19. Quantitative assessment of the pool size and subset distribution of cytolytic T lymphocytes within human resting or alloactivated peripheral blood T cell populations
20. Limiting dilution assays for the determination of immunocompetent cell frequencies: I. Data analysis
21. Quantification of antigen-reactive cells among human T lymphocytes
22. Activation-induced apoptosis in lymphocytes
23. Rapid determination of Epstein-Barr virus-specific CD8(+) T-cell frequencies by flow cytometry
24. + T cells specific for EBV in healthy virus carriers
25. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells
26. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
27. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: A four-centre comparative trial
28. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
29. Identification of functional subsets by flow cytometry: Intracellular detection of cytokine expression
30. + T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
31. Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion
32. T cell memory
33. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
34. Serial triggering of many T-cell receptors by a few peptide-MHC complexes
35. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
36. + T cells following vaccination with antigenic peptide
37. + T cells in melanoma patients
38. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma
39. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers
40. High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells
41. + melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy
42. An antigen-targeted approach to adoptive transfer therapy of cancer
43. Melanocyte destruction after antigen-specific immunotherapy of melanoma, Direct evidence of T cell-mediated vitiligo
44. Human tumor antigens recognized by T cells
45. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens
46. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
47. + T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients
48. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
49. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
50. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
51. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
52. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
53. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
54. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response
55. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1
56. Structure, chromosomal localization, and expression of 12 genes of the MAGE family
57. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma
58. Frequent cytolytic T-cell responses to peptide MAGE-A10 254-262 in melanoma
59. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene
60. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma
61. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
62. Telomere length regulation
63. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
64. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens
65. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
66. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
67. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
68. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
69. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
70. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
71. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
72. + T cells
73. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases
74. Is cancer dangerous to the immune system?
75. Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node
76. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes
77. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas
78. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
79. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo
80. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
81. + cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo
82. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
83. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
84. + T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells
85. CD28-T lymphocytes. Antigenic and functional properties
86. Faces and phases of human CD8 T-cell development
87. CD8high+ (CD57+) T cells in patients with rheumatoid arthritis
88. + T cells closely correlates with CD56 surface expression
89. In situ detection of virus- and tumor-specific T-cell immunity
90. Cutting edge: In situ tetramer staining of antigen-specific T cells in tissues
91. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
92. + T cells during the primary immune response to Epstein-Barr virus in vivo
93. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
94. Antiviral immunity
95. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
96. + T cell response to NY-ESO-1: Relative antigenicity and in vitro immunogenicity of natural and analogue sequences